Quality of life in long-term breast cancer survivors – a 10-year longitudinal population-based study

Koch, Lena; Jansen, Lina; Herrmann, A.; Stegmaier, Christa; Holleczek, Bernd; Schnittger, Susanne; Brenner, Hermann; Arndt, Volker

doi:10.3109/0284186x.2013.774461

Cited by 155 publications

(177 citation statements)

References 31 publications

Supporting

Mentioning

154

Contrasting

Unclassified

Order By: Relevance

“…The health-related quality of life of breast cancer patients has been investigated for many years [27,28]; it is particularly important for patients with metastatic disease as the primary goal of therapy for these patients is to provide them with the best possible quality of life during their remaining lifespan [12][13][14]. Adjuvant therapy can also lead to a significant deterioration in patientsʼ quality of life [29].…”

Section: Health-related Quality Of Life In Metastatic and Adjuvant Brmentioning

confidence: 99%

Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients

Wallwiener

Simoes

Sokolov

et al. 2016

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Einleitung: Liegt bei einer Krebserkrankung bereits ein fortgeschrittenes Stadium vor und ist somit eine primäre Heilung nicht mehr möglich, steht die Erhaltung der Lebensqualität im Fokus. Gerade beim Mammakarzinom sind durch die verbesserten neuen Therapien auch im metastasierten Stadium noch längere stabile Verläufe möglich. Ziel dieser Studie war es deshalb, einerseits die Lebensqualität der Patientinnen durch einen Vergleich mit Daten der Gesamtbevölkerung darzustellen und andererseits Unterschiede zwischen den verschiedenen Erhebungsinstrumenten aufzuzeigen. Material und Methoden: Insgesamt wurden n = 96 Brustkrebspatientinnen in metastasierter oder adjuvanter Situation hinsichtlich ihrer Lebensqualität befragt. Dabei kamen die etablierten Erhebungsinstrumente EORTC QLQ-C30, EORTC QLQ-BR23, EQ-5D-5L und EQ-VAS zum Einsatz, wobei alle Patientinnen alle Bögen ausfüllten. Die statistische Analyse erfolgte mittels MS Excel und SPSS. Ergebnisse: Obwohl die Bögen zum gleichen Zeitpunkt ausgefüllt wurden, zeigten sich deutliche Unterschiede im Belastungsniveau in Abhängigkeit zum angewandten Bogen. Beim Einsatz des EQ VAS wurde der aktuelle Gesundheitsstatus signifikant besser beurteilt als beim EORTC QLQ-C30. Insgesamt gestaltete sich die Lebensqualität der Patientinnen in allen Dimensionen als optimierungsbedürftig und war in allen Bereichen signifikant schlechter als in der Referenzbevölkerung. Schlussfolgerung: Um die Lebensqualität von metastasierten Patientinnen zu verbessern, ergibt sich die die Notwendigkeit des beständigen Therapieerfolg-Monitorings. Von Relevanz ist die Wahl des Erhebungsinstruments, da in Abhängigkeit vom Erhebungsinstrument unterschiedliche Werte ermittelt wurden.

show abstract

Section: Health-related Quality Of Life In Metastatic and Adjuvant Brmentioning

confidence: 99%

Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients

Wallwiener

Simoes

Sokolov

et al. 2016

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

“…Improvement of cutaneous symptoms also translated into improvements of QLQ-BR23 scores of over 40% for body image, arm symptoms, breast symptoms and symptoms associated with systemic therapy, and were confirmed by improvements of 21% in psychological well-being measured by the PGWBI scale. Although some studies have reported that QoL improves with long-term survival after breast cancer treatment (Grimison & Stockler, 2007;Kornblith et al, 2003), more recent studies have shown that breast cancer survivors continue to experience impaired physical and social functioning 5-10 years after the end of therapy (Koch et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study

et al. 2017

View full text Add to dashboard Cite

This study investigated the efficacy of post-treatment hydrotherapy as supportive care for management of persistent/long-lasting dermatologic adverse events (dAEs) induced in breast cancer survivors by adjuvant therapy, and its impact on quality of life (QoL).Patients in complete remission after standardised (neo)adjuvant chemotherapy, surgery and radiotherapy combination treatment for infiltrating HR+/HER2-breast carcinoma were enrolled in this randomised, multicentre controlled study 1-5 weeks after completing radiotherapy. The control group (CG, n = 33) received best supportive care and the treatment group (HG, n = 35) received 3-weeks of specific hydrotherapy. The primary criterion was change in QoL (QLQ-BR23) after hydrotherapy. Clinical grading of dAEs, cancer-related QoL (QLQ-C30), dermatologic QoL (DLQI) and general psychological well-being (PGWBI) were assessed. Significant dAEs were found at inclusion in both groups (n = 261). Most items showed significantly greater improvement in the HG

show abstract

“…At 10 years postdiagnosis, breast cancer survivors had more severe fatigue, nausea/vomiting, pain, insomnia and financial difficulties and lower physical, role, emotional, cognitive and social functioning (all p < 0.01 compared to controls). However, breast cancer survivors and controls had similar global health scores suggesting that symptom burden may not translate into worse quality of life [15].…”

Section: Breast Cancermentioning

confidence: 99%

“…In a cross-sectional study, Koch et al used the EORTC QLQ-C30 and QLQ-BR23 to compare quality of life in 387 long-term breast cancer survivors versus agematched controls without cancer [15]. At 10 years postdiagnosis, breast cancer survivors had more severe fatigue, nausea/vomiting, pain, insomnia and financial difficulties and lower physical, role, emotional, cognitive and social functioning (all p < 0.01 compared to controls).…”

Section: Breast Cancermentioning

confidence: 99%

Patient-reported outcomes in cancer survivorship

Gordon

Chen

2017

Acta Oncologica

View full text Add to dashboard Cite

Background: There are currently 33 million cancer survivors worldwide. With improvements in early cancer detection and treatments, patients are living longer -and it is well-recognized that many survivors develop short-and long-term physical, psychosocial and spiritual effects as a result of their diagnoses and treatments. There is increasing awareness of the importance of using patient-reported outcomes (PROs) to accurately assess these effects in cancer survivors. Validated patient-reported outcome instruments: Traditionally, physicians have assessed the acute and late side effects of cancer treatments with standardized scales such as the CTCAE. However, multiple studies have demonstrated that PROs more accurately capture patient symptoms than physician assessment. In this article we describe frequently used, validated, general and cancer-specific PRO instruments that assess symptoms. We describe additional PRO instruments that assess unmet needs, interpersonal relationship issues, and psychosocial and financial problems. Published studies using these instruments have identified issues commonly faced by cancer survivors worldwide. Discussion and summary: While PROs are increasingly used in research, further efforts are needed to integrate PRO assessment into routine clinical care, so that timely and accurate assessments can translate into better management of issues -ultimately improving the lives of cancer survivors.

show abstract

Quality of life in long-term breast cancer survivors – a 10-year longitudinal population-based study

Cited by 155 publications

References 31 publications

Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients

Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients

Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study

Patient-reported outcomes in cancer survivorship

Contact Info

Product

Resources

About